Abstract
NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.
Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.
Current Pharmaceutical Design
Title:From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights
Volume: 19 Issue: 29
Author(s): Samuele De Minicis, Chris Day and Gianluca Svegliati-Baroni
Affiliation:
Keywords: NAFLD, NASH, fibrosis, microbiota, bacterial translocation.
Abstract: NAFLD is the most common liver disease worldwide but it is the potential evolution to cirrhosis and hepatocellular carcinoma (HCC) that makes NAFLD of such clinical importance. The current work provides an overview of the main mechanims and potential therapeutical insights involved in NAFLD, NASH, fibrosis and HCC progression.
Export Options
About this article
Cite this article as:
De Minicis Samuele, Day Chris and Svegliati-Baroni Gianluca, From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights, Current Pharmaceutical Design 2013; 19 (29) . https://dx.doi.org/10.2174/1381612811319290006
DOI https://dx.doi.org/10.2174/1381612811319290006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Synthesis and Anti – Tumour Activity of Novel Camptothecin – Bile Acid Analogues
Letters in Drug Design & Discovery Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Recent Advances on Dark and Light-Activated Cytotoxity of Imidazole- Containing Ruthenium Complexes
Mini-Reviews in Medicinal Chemistry Retroviral Protein Transfer: Falling Apart to Make an Impact
Current Gene Therapy Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Natural Products, Synthetic and Non-Nucleoside Compounds as Inhibitors of Enzymes Related to DNA: Update 2013
Current Enzyme Inhibition Delivery Systems for Birch-bark Triterpenoids and their Derivatives in Anticancer Research
Current Medicinal Chemistry Potential Therapeutic Approaches for the Treatment of Acute Myeloid Leukemia with AML1-ETO Translocation
Current Cancer Drug Targets DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) HSV-1 Based Amplicon Vectors as an Alternative System for the Expression of Functional HCV Proteins
Current Gene Therapy Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Current Pharmaceutical Design Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems
Current Gene Therapy Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued)